Avraham Pharmaceuticals Ltd.  has closed an investment round of approximately $4.0 million. Investors in the round include Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries, Integra Holdings, Yissum’s biotech holdings company, the Technion Research and Development Foundation Ltd. (TRDF)...

BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced positive results from its HOPEMD Phase 2 six-month open-label clinical study in patients with oculopharyngeal muscular dystrophy (OPMD), a rare progressive muscle-wasting disease characterized by swallowing difficulties (dysphagia), leading to the risk of aspiration of food into the lungs,...

Enzymotec announced that InCogTM, an innovative lipid composition that is intended to mimic certain characteristics of human breast milk contributing to cognitive development, demonstrated enhanced brain development and improved survival in a preclinical study. The study evaluated the effects of InCogTM in a term and preterm piglet model relevant for...

Can-Fite has submitted to the European Medicines Agency (EMA) a protocol design for its Phase III trial and Registration Plan for the Company’s lead compound CF101 in the treatment of rheumatoid arthritis following a pre-submission meeting with the EMA. The global trial is expected to commence in either the second...

Israeli big data and intensive care analytics startup Intensix has signed an agreement with Mayo Clinic in the US to commence a study of early predictions of life-threatening complications in a critical care setting. The study will focus on the feasibility of using the Intensix platform to predict patient deterioration...